BETHESDA, Md., April 18, 2013 — Northwest
Biotherapeutics (NASDAQ: NWBO) (NW Bio), a biotechnology company
developing DCVax® personalized immune therapies for solid tumor
cancers, announced today that on April 17, 2013, it entered into an
agreement with one healthcare-dedicated institutional investor for
a registered direct placement of $10 million of common stock at the
closing market price of $3.90 per share.

In addition, the Company will issue to the investor warrant
coverage of 40% to purchase shares of common stock. The warrants
have an exercise price of $4.29 per share and are exercisable
beginning six months after closing, with a term of five years.

The placement is expected to close on or before April 19, 2013,
subject to satisfaction of customary closing conditions.

H.C. Wainwright & Co., LLC acted as the exclusive placement
agent for the transaction.

The securities described above are being offered pursuant to a
shelf registration statement (File No. 333-185898), which was
declared effective by the United States Securities and Exchange
Commission (“SEC”) on February 13, 2013.  This press release
shall not constitute an offer to sell or the solicitation of an
offer to buy any of the securities described herein, nor shall
there be any sale of these securities in any state or jurisdiction
in which such offer, solicitation or sale would be unlawful prior
to registration or qualification under the securities laws of any
such state or jurisdiction.  When filed with the SEC, copies
of the prospectus supplement and the accompanying base prospectus
relating to this offering may be obtained at the SEC’s website at
http://www.sec.gov or by request at H.C. Wainwright & Co.,
LLC 570 Lexington Avenue, 20th Floor, New York, NY 10022 or at
placements@hcwco.com.

About Northwest Biotherapeutics

Northwest Biotherapeutics is a biotechnology company focused on
developing immunotherapy products to treat cancers more effectively
than current treatments, without toxicities of the kind associated
with chemotherapies, and on a cost-effective basis, in both the
U.S. and Europe. The Company has a broad platform technology for
DCVax dendritic cell-based vaccines. The Company’s lead program is
a 312-patient Phase III trial in newly diagnosed Glioblastoma
multiforme (GBM). GBM is the most aggressive and lethal brain
cancer. The Company also previously received clearance from the FDA
for a 612-patient Phase III trial in prostate cancer, and clearance
from the FDA for Phase I/II trials in multiple other cancers. The
Company has also conducted a Phase I/II trial with DCVax for
metastatic ovarian cancer together with the University of
Pennsylvania.

Disclaimer

Statements made in this news release that are not historical
facts, including statements concerning future treatment of patients
using DCVax and future clinical trials, are forward-looking
statements within the meaning of the Private Securities Litigation
Reform Act of 1995. Words such as “expect,” “believe,” “intend,”
“plan,” “continue,” “may,” “will,” “anticipate,” and similar
expressions are intended to identify forward-looking statements.
Actual results may differ materially from those projected in any
forward-looking statement. Specifically, there are a number of
important factors that could cause actual results to differ
materially from those anticipated, such as the Company’s ability to
raise additional capital, risks related to the Company’s ability to
enroll patients in its clinical trials and complete the trials on a
timely basis, the uncertainty of the clinical trials process,
uncertainties about the timely performance of third parties, and
whether the Company’s products will demonstrate safety and
efficacy. Additional information on these and other factors,
including Risk Factors, which could affect the Company’s results,
is included in its Securities and Exchange Commission (“SEC”)
filings. Finally, there may be other factors not mentioned above or
included in the Company’s SEC filings that may cause actual results
to differ materially from those projected in any forward-looking
statement. You should not place undue reliance on any
forward-looking statements. The Company assumes no obligation to
update any forward-looking statements as a result of new
information, future events or developments, except as required by
securities laws.